{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:10Z","timestamp":1791331690838,"version":"4.3.1"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.pharmthera.2011.04.002","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T03:20:07Z","timestamp":1303183207000},"page":"50-60","source":"Crossref","is-referenced-by-count":47,"title":["The role of the renin\u2013angiotensin system in thoracic aortic aneurysms: Clinical implications"],"prefix":"10.1016","volume":"131","author":[{"given":"Els","family":"Moltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Essers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep H.M.","family":"van Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien W.","family":"Roos-Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2011.04.002_bb0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.athoracsur.2007.05.038","article-title":"Safety of thoracic aortic surgery in the present era","volume":"84","author":"Achneck","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/hrt.73.3.265","article-title":"Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome","volume":"73","author":"Adams","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S3056","article-title":"Arterial stiffness, hypertension, and rational use of nebivolol","volume":"5","author":"Agabiti-Rosei","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0020","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.298.13.1539","article-title":"Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial","volume":"298","author":"Ahimastos","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.athoracsur.2006.04.098","article-title":"Familial thoracic aortic aneurysms and dissections\u2014incidence, modes of inheritance, and phenotypic patterns","volume":"82","author":"Albornoz","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0030","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/sj.embor.7400033","article-title":"Fibulins: physiological and disease perspectives","volume":"4","author":"Argraves","year":"2003","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0035","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1161\/01.CIR.0000128696.12245.57","article-title":"Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries","volume":"109","author":"Batenburg","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0040","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/eurheartj\/ehq249","article-title":"ESC guidelines for the management of grown-up congenital heart disease (new version 2010): the Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC)","volume":"31","author":"Baumgartner","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0002-9149(93)90896-K","article-title":"Familiar clustering of aortic dissection in polycystic kidney disease","volume":"72","author":"Biagini","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0050","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"Bonow","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.31.1.181","article-title":"Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis","volume":"31","author":"Border","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1476-5381.2009.00575.x","article-title":"Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats","volume":"159","author":"Bosnyak","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0065","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtcvs.2009.03.014","article-title":"Stent graft repair of descending aortic dissection in patients with Marfan syndrome: an effective alternative to open reoperation?","volume":"138","author":"Botta","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0070","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.HYP.0000182661.98259.4f","article-title":"Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II","volume":"46","author":"Chai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0080","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.avsg.2008.04.005","article-title":"Ten-year epidemiological review of in-hospital patients with Marfan syndrome","volume":"22","author":"Chan","year":"2008","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BJ20090993","article-title":"Fibulin-4 regulates expression of the tropoelastin gene and consequent elastic-fibre formation by human fibroblasts","volume":"423","author":"Chen","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4065\/79.2.176","article-title":"Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture","volume":"79","author":"Clouse","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0095","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/ng1194-264","article-title":"A second locus for Marfan syndrome maps to chromosome 3p24.2-p25","volume":"8","author":"Collod","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ng1764","article-title":"Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome","volume":"38","author":"Coucke","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1357-2725(02)00178-4","article-title":"Local renin\u2013angiotensin systems: the unanswered questions","volume":"35","author":"Danser","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FJC.0b013e318070d1d3","article-title":"Novel drugs targeting hypertension: renin inhibitors","volume":"50","author":"Danser","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.HYP.24.1.37","article-title":"Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis","volume":"24","author":"Danser","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pharmthera.2006.12.001","article-title":"ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?","volume":"113","author":"Danser","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0735-1097(01)01108-1","article-title":"Pulse pressure\u2014a review of mechanisms and clinical relevance","volume":"37","author":"Dart","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0135","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/ajmg.a.31980","article-title":"Compound heterozygous mutations in fibulin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa","volume":"143","author":"Dasouki","year":"2007","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.tcm.2004.01.002","article-title":"Angiotensin II-mediated development of vascular diseases","volume":"14","author":"Daugherty","year":"2004","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11906-004-0038-0","article-title":"Angiotensin II and abdominal aortic aneurysms","volume":"6","author":"Daugherty","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjp.0704331","article-title":"Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis","volume":"134","author":"Daugherty","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0155","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.HYP.29.6.1240","article-title":"Renin\u2013angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I","volume":"29","author":"de Lannoy","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acvd.2010.04.008","article-title":"Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome","volume":"103","author":"Detaint","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0170","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00270-008-9456-8","article-title":"Endovascular stent graft placement in the treatment of ruptured tuberculous pseudoaneurysm of the descending thoracic aorta: case report and review of the literature","volume":"32","author":"Dogan","year":"2009","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0175","first-page":"A14647","article-title":"Calcium channel blockers exacerbate aortic disease and cause premature lethality in Marfan syndrome","volume":"122","author":"Doyle","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/sj.bjp.0706036","article-title":"AT(2) receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension","volume":"144","author":"Duke","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrcardio.2009.191","article-title":"Cellular and molecular mechanisms of thoracic aortic aneurysms","volume":"6","author":"El-Hamamsy","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2265.2001.01154.x","article-title":"Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome","volume":"54","author":"Elsheikh","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/ATVBAHA.109.186593","article-title":"TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice","volume":"29","author":"Frutkin","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0200","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2459\/JCM.0b013e3283232a45","article-title":"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations","volume":"10","author":"Gambarin","year":"2009","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature03940","article-title":"Mutations in NOTCH1 cause aortic valve disease","volume":"437","author":"Garg","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0210","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1097\/HJH.0b013e3283311ba1","article-title":"Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage","volume":"27","author":"Gelosa","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-2-32","article-title":"Ehlers\u2013Danlos syndrome type IV","volume":"2","author":"Germain","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI115881","article-title":"Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II","volume":"90","author":"Gibbons","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jtcvs.2010.08.007","article-title":"Superior nationwide outcomes of endovascular versus open repair for isolated descending thoracic aortic aneurysm in 11,669 patients","volume":"140","author":"Gopaldas","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0235","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1161\/01.CIR.103.20.2461","article-title":"Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q13-14","volume":"103","author":"Guo","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0240","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/ng.2007.6","article-title":"Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections","volume":"39","author":"Guo","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0250","first-page":"S963","article-title":"AT2 Signaling is a positive prognostic and therapeutic modifier of Marfan syndrome: lessons on the inequality of ACEi and ARBs","volume":"120","author":"Habashi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.RES.0000260181.19449.95","article-title":"Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice","volume":"100","author":"Hanada","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0260","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/01.CIR.0000078634.33124.95","article-title":"Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2) to 3p24-25","volume":"107","author":"Hasham","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0265","doi-asserted-by":"crossref","first-page":"21985","DOI":"10.1074\/jbc.271.36.21985","article-title":"Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function","volume":"271","author":"Hayashida","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0270","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2010.02.015","volume":"55","author":"Hiratzka","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0275","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1242\/jcs.074773","article-title":"Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity","volume":"123","author":"Horbelt","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0280","doi-asserted-by":"crossref","first-page":"19029","DOI":"10.1073\/pnas.0908268106","article-title":"Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase","volume":"106","author":"Horiguchi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0285","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1399-0004.2009.01204.x","article-title":"Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous fibulin-4 gene mutation","volume":"76","author":"Hoyer","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0290","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCRESAHA.109.207852","article-title":"Fibulin-4 deficiency results in ascending aortic aneurysms. A potential link between abnormal smooth muscle cell phenotype and aneurysm progression","volume":"106","author":"Huang","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0295","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1086\/504304","article-title":"Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome","volume":"78","author":"Hucthagowder","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0300","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1583\/04-1415MR.1","article-title":"Stent-grafts in patients with marfan syndrome","volume":"12","author":"Ince","year":"2005","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0305","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/01.CIR.0000154569.08857.7A","article-title":"Thoracic and abdominal aortic aneurysms","volume":"111","author":"Isselbacher","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0310","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1067\/mva.1991.26737","volume":"13","author":"Johnston","year":"1991","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0315","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/ATVBAHA.107.155564","article-title":"Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts","volume":"28","author":"Jones","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1172\/JCI200420641","article-title":"Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome","volume":"114","author":"Judge","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0325","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1172\/JCI117251","article-title":"Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells","volume":"93","author":"Kagami","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0330","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.108.784868","article-title":"Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin\u2013angiotensin system in myocardial infarction?","volume":"118","author":"Kaschina","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0335","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.atherosclerosis.2009.01.003","article-title":"Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components","volume":"205","author":"Kaschina","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0340","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.104.506345","article-title":"Mapping of familial thoracic aortic aneurysm\/dissection with patent ductus arteriosus to 16p12.2-p13.13","volume":"112","author":"Khau Van Kien","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0345","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2353\/ajpath.2008.070762","article-title":"Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK\/p38 MAP kinase pathway","volume":"172","author":"Koka","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0350","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.109.133892","article-title":"Cardiac renin levels are not influenced by the amount of resident mast cells","volume":"54","author":"Krop","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0355","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejphar.2010.04.058","article-title":"Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release","volume":"640","author":"Krop","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0365","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0370","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.amjcard.2006.08.048","article-title":"Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome","volume":"99","author":"Ladouceur","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0375","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0380","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/01.hjh.0000182521.44440.c5","article-title":"Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats","volume":"23","author":"Lavoie","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0385","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1673-8527(09)60078-3","article-title":"TGF-beta signaling in aortic aneurysm: another round of controversy","volume":"37","author":"Lin","year":"2010","journal-title":"J Genet Genomics"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0390","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ng1511","article-title":"A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2","volume":"37","author":"Loeys","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0395","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor","volume":"355","author":"Loeys","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0400","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11906-008-0020-3","article-title":"The role of the renin\u2013angiotensin system in aortic aneurysmal diseases","volume":"10","author":"Lu","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0405","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI25713","article-title":"Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia\/reperfusion","volume":"116","author":"Mackins","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/14779072.1.1.65","article-title":"Antihypertensive drugs and arterial stiffness","volume":"1","author":"Mahmud","year":"2003","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0415","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.108.841981","article-title":"Circulating transforming growth factor-beta in Marfan syndrome","volume":"120","author":"Matt","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0420","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/CIRCULATIONAHA.106.685487","article-title":"Aortic dilatation and dissection in Turner syndrome","volume":"116","author":"Matura","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0425","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jtcvs.2007.02.041","article-title":"Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms","volume":"134","author":"McKellar","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0430","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/MCB.26.5.1700-1709.2006","article-title":"Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice","volume":"26","author":"McLaughlin","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0435","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1161\/01.CIR.0000155243.70456.F4","article-title":"Treatment of aortic disease in patients with Marfan syndrome","volume":"111","author":"Milewicz","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0440","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.genom.8.080706.092303","article-title":"Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction","volume":"9","author":"Milewicz","year":"2008","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0445","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.145037","article-title":"Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation","volume":"55","author":"Moltzer","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0450","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/oxfordjournals.eurheartj.a059462","article-title":"Aneurysms of the sinuses of Valsalva in Noonan's syndrome","volume":"10","author":"Morgan","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0455","doi-asserted-by":"crossref","first-page":"I282","DOI":"10.1161\/hc37t1.094856","article-title":"Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome","volume":"104","author":"Nagashima","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0460","series-title":"WISQARS Leading Causes of Death Reports","author":"National Center for Injury Prevention and Control","year":"2007"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0465","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0470","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI200422715","article-title":"TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome","volume":"114","author":"Ng","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0475","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/hrt.82.1.19","article-title":"Aortic root dilatation in young men with normally functioning bicuspid aortic valves","volume":"82","author":"Nistri","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0480","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.ATV.0000055441.28842.0A","article-title":"Bicuspid aortic valve associated with aortic dilatation: a community-based study","volume":"23","author":"Nkomo","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0485","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ehj.2004.04.033","article-title":"Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome","volume":"25","author":"Nollen","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0490","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0140-6736(10)60960-9","article-title":"Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers\u2013Danlos syndrome: a prospective randomised, open, blinded-endpoints trial","volume":"376","author":"Ong","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0495","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.32.3.467","article-title":"Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats","volume":"32","author":"Otsuka","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0500","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.HYP.0000196950.48596.21","article-title":"Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat","volume":"47","author":"Padia","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0505","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/CIRCULATIONAHA.105.537340","article-title":"Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections","volume":"112","author":"Pannu","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0510","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/hmg\/ddm201","article-title":"MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II","volume":"16","author":"Pannu","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0515","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM200003093421001","article-title":"Clinical and genetic features of Ehlers\u2013Danlos syndrome type IV, the vascular type","volume":"342","author":"Pepin","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0520","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ng1097-218","article-title":"Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome","volume":"17","author":"Pereira","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0525","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1073\/pnas.96.7.3819","article-title":"Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1","volume":"96","author":"Pereira","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0530","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1523-1755.2000.00994.x","article-title":"Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis","volume":"57","author":"Peters","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0535","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/HYPERTENSIONAHA.106.085035","article-title":"Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats","volume":"50","author":"Pinaud","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0540","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-11-3","article-title":"Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial","volume":"11","author":"Radonic","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/01.CIR.85.1.205","article-title":"Are aortic aneurysms caused by atherosclerosis?","volume":"85","author":"Reed","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0550","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ejhg.2010.45","article-title":"Altered TGFbeta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency","volume":"18","author":"Renard","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0555","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/humu.10113","article-title":"Mutations of FBN1 and genotype\u2013phenotype correlations in Marfan syndrome and related fibrillinopathies","volume":"20","author":"Robinson","year":"2002","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0560","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/01.CIR.0000165133.84978.E2","article-title":"Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism","volume":"111","author":"Rodriguez-Vita","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0565","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1358\/dnp.2010.23.2.1475901","article-title":"The angiotensin AT2 receptor in inflammation","volume":"23","author":"Rompe","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0570","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0002-9149(99)00101-0","article-title":"Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome","volume":"83","author":"Rossi-Foulkes","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0575","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cardiores.2007.02.008","article-title":"TGF-beta signaling in vascular fibrosis","volume":"74","author":"Ruiz-Ortega","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"suppl I","key":"10.1016\/j.pharmthera.2011.04.002_bb0580","first-page":"I-126","article-title":"Apoptosis of medial smooth muscle cells in dilated ascending aortas of patients with Marfan's syndrome and annulo-aortic ectasia","volume":"96","author":"Sakomura","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0585","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0002-9149(94)90762-5","article-title":"Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome","volume":"74","author":"Salim","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0590","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0895-7061(02)02972-2","article-title":"Cardiac angiotensin II: an intracrine hormone?","volume":"15","author":"Schuijt","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0595","doi-asserted-by":"crossref","first-page":"H2590","DOI":"10.1152\/ajpheart.2001.281.6.H2590","article-title":"AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction","volume":"281","author":"Schuijt","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpeds.2006.09.003","article-title":"Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome","volume":"150","author":"Selamet Tierney","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0605","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2011.04.002_bb0610","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/01.hjh.0000388495.66330.63","article-title":"The angiotensin AT2 receptor in left ventricular hypertrophy","volume":"28","author":"Steckelings","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.semvascsurg.2009.04.006","article-title":"Thoracic aortic dissection: long-term results of endovascular and open repair","volume":"22","author":"Subramanian","year":"2009","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0620","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1006\/jmcc.1998.0721","article-title":"Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart","volume":"30","author":"Sun","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0625","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/00313020600820898","article-title":"Review of isolated ascending aortitis: differential diagnosis, including syphilitic, Takayasu's and giant cell aortitis","volume":"38","author":"Tavora","year":"2006","journal-title":"Pathology"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0630","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejvs.2007.07.022","article-title":"Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis","volume":"35","author":"Thompson","year":"2008","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0635","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sj.bjp.0706762","article-title":"AT(2) receptor-mediated vasodilation in the mouse heart depends on AT(1A) receptor activation","volume":"148","author":"van Esch","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0640","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cvr\/cvq004","article-title":"Cardiac phenotype and angiotensin II levels in AT1a, AT1b and AT2 receptor single, double and triple knockouts","volume":"86","author":"van Esch","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0645","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.HYP.35.3.717","article-title":"Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries","volume":"35","author":"van Geel","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0650","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.102.13.1556","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II","volume":"102","author":"van Kats","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0655","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1046\/j.1523-1755.2001.00049.x","article-title":"Intrarenal angiotensin II: interstitial and cellular levels and site of production","volume":"60","author":"van Kats","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0660","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00004872-200103001-00010","article-title":"Subcellular localization of angiotensin II in kidney and adrenal","volume":"19","author":"van Kats","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0665","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.amjhyper.2005.02.005","article-title":"Adrenal angiotensin: origin and site of generation","volume":"18","author":"van Kats","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0670","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1006\/jmcc.1997.0448","article-title":"Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts","volume":"29","author":"van Kesteren","year":"1997","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0675","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.103.20.2469","article-title":"Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder","volume":"103","author":"Vaughan","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0680","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.0709739105","article-title":"Mast cell renin and a local renin\u2013angiotensin system in the airway: role in bronchoconstriction","volume":"105","author":"Veerappan","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0685","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/jm031031i","article-title":"First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo","volume":"47","author":"Wan","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0690","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.105.579342","article-title":"Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population","volume":"113","author":"Willum-Hansen","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0695","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/01.HYP.0000120963.09029.ca","article-title":"Angiotensin II and cell cycle regulation","volume":"43","author":"Wolf","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0700","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.amjcard.2005.01.032","article-title":"Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome","volume":"95","author":"Yetman","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0705","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.CIR.0000156503.62815.48","article-title":"High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats","volume":"111","author":"You","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0710","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/01.CIR.0000141593.05085.87","article-title":"Surgery for aneurysms of the aortic root: a 30-year experience","volume":"110","author":"Zehr","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2011.04.002_bb0715","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ng1721","article-title":"Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm\/aortic dissection and patent ductus arteriosus","volume":"38","author":"Zhu","year":"2006","journal-title":"Nat Genet"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725811000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725811000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T04:15:04Z","timestamp":1560140104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725811000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0163725811000817"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2011.04.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}